Evaluation of the Changes in Matrix Metalloproteinase-9 Levels With Salvadora Persica (Miswak) in Periodontal Fibroblasts and Gingival Crevicular Fluid in Patients With Periodontitis

Despite the clinical benefits mentioned, miswak use have been associated with some drawbacks such as clinical attachment loss; improper use of miswak over a long period can result in a risk of oral tissues injury. To date, there is a lack of comprehensive evidence-based literature to guide a safe and effective accepted practice that can subsequently be used as oral hygiene instructions for miswak users. Correlation between the in vitro and in vivo findings will be performed to evaluate the translational relationship between the effects of miswak on periodontal fibroblast inflammatory activity and the corresponding clinical and biomarker outcomes in patients with periodontitis. Matrix metalloproteinase-9 (MMP-9) and prostaglandin E2 (PGE2) levels obtained from periodontal fibroblast cultures will be compared with gingival crevicular fluid (GCF) MMP-9 and PGE2 levels and clinical periodontal parameters, including probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), and plaque index (PI).

Inclusion criteria

• Stage II or III, grade B periodontitis

Exclusion criteria

• Have poor manual dexterity

• Systemic condition that may affect healing
• Administration of certain medications that may modify the outcomes
• Smoking patients
• Pregnant females
• Periapical involvement in teeth
• Habitual or experienced users of miswak chewing sticks
• History of topical or systemic chemical plaque control during the past 6 months
• History of periodontal surgery during the past 6 months
• Local risk factor that interfere with accessibility for regular personal plaque control aids